REGAL CORE Inc. (Shibuya-ku, Tokyo, President and CEO: Hayato Tanoue), which handles pharmaceutical and medical device act checks, regularly conducts surveys on the advertising status of article LPs (landing pages) [1] that may contain expressions violating laws such as the Pharmaceutical and Medical Device Act and the Premiums and Representations Act. We report the results. Survey Results Following the previous survey, the article LPs investigated this time also showed the distribution of content that is highly likely to be problematic under the Pharmaceutical and Medical Device Act and the Premiums and Representations Act. Details are summarized below with specific examples. Survey Method Survey Period: May 2026 - July 2026 Survey Target: Each time, multiple web media are arbitrarily selected, and article LPs of advertisements distributed primarily through recommendation widgets posted on those web media. Survey Method: Every half month, we identify article LPs of advertised products posted on multiple web media, and examine and evaluate their appeal expressions from the perspective of protecting users based on the Pharmaceutical and Medical Device Act and the Premiums and Representations Act to see if there are any problematic expressions. Details of Findings We summarize some of the appeal expressions contained in the article LPs obtained during the survey period that are considered to be in violation of laws and regulations. [2] In addition, the following appeal expressions have been confirmed frequently, including those pointed out in the past. For products falling under health foods, expressions that violate claims of medicinal efficacy and effects (Pharmaceutical and Medical Device Act), exaggerated claims (Health Promotion Act), or misrepresentation of superiority (Premiums and Representations Act) a. Expressions claiming effects on specific body parts or bodily functions that cannot be claimed. Example 1: Expressions such as "utilizing the function of fema